CING

SEC filing CING Reports $30M Cash, FDA CRL for CTx-1301 ADHD Drug No Safety Issues, CMC Requests Only

6h ago

SEC filing CING Reports Board Reduction to 5 Directors, Appoints New Chairman, Jeff Hargroves Reappointed Class II Director

13d ago

SEC filing CING Q1 2026 Net Loss $9.3M, Cash $25.9M, R&D $2.2M, G&A $5.7M

19d ago

SEC filing CING Announces $12M Private Placement Financing, 80% Warrant Coverage, FDA NDA Review for ADHD Treatment CTx-1301

105d ago

News Why This Vanguard ETF Doesn't Belong in Your Portfolio

112d ago

News This Low-Cost Vanguard Fund Can Be a No-Brainer Option for Long-Term Investors

115d ago

SEC filing CING Enters $12M Private Placement, Sells 2.1M Shares, 973 Preferred Shares, 1.9M Warrants at $5.14/Share

124d ago